James Frank

Service capacity and amyloid-related imaging abnormality burden of antiamyloid therapy for early Alzheimer’s disease: a parameterised modelling study of a one-million-person

Background Anti-amyloid monoclonal antibodies are the first therapies to modify the biology of Alzheimer’s disease, but their delivery requires biomarker confirmation, repeated intravenous administration and scheduled magnetic resonance imaging (MRI) surveillance. The service capacity implied by adoption at population...